ABSTRACT

Despite all advancement in ovarian stimulation programmes and laboratory techniques, the success of assis-ted reproductive techniques remains limited. Today, the primary stimulating agents adopted as standard are clomiphene citrate and gonadotrophins. In some patients treated with stimulation protocols using those two agents, adequate follicular development cannot be maintained or adequate amount and/or quality of oocy-tes cannot be achieved. Hence, development of some alternative treatment strategies in assisted reproduc-tive technologies has been needed. Nowadays, those treatment methods are used in anovulatory infertile patients and poor responders. Some additional agents are used in those patients in order to increase the amount and quality of achieved oocytes while decreasing treatment costs. In this sense, the best known ad-ditional agents are metformin, aromatase inhibitors, dehydrepiandrosterone, androgens, growth hormone, corticosteroids, and antioxidants.